Baird Financial Group Inc. Boosts Stake in Sanofi $SNY

Key Points

• Baird Financial Group Inc. increased its stake in Sanofi by 14.8% in Q1, owning 164,161 shares valued at approximately $9.1 million.
• Sanofi's most recent earnings report showed $0.90 earnings per share, missing estimates, with a decline in revenue of 7% year-over-year.
• Several analysts upgraded Sanofi's stock rating, with an average price target of $62.00 and three ratings classified as Strong Buy.

Baird Financial Group Inc. raised its holdings in Sanofi (NASDAQ:SNY - Free Report) by 14.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 164,161 shares of the company's stock after acquiring an additional 21,121 shares during the period. Baird Financial Group Inc.'s holdings in Sanofi were worth $9,104,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. grew its stake in Sanofi by 124.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock worth $1,344,000 after buying an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC increased its stake in Sanofi by 130.5% in the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock valued at $568,000 after acquiring an additional 5,794 shares during the last quarter. Ballentine Partners LLC raised its position in Sanofi by 68.7% during the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after purchasing an additional 10,617 shares in the last quarter. Sowell Financial Services LLC bought a new stake in Sanofi during the first quarter worth about $328,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Sanofi by 66.2% in the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after purchasing an additional 2,476 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analyst Upgrades and Downgrades

SNY has been the topic of several recent research reports. Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. Finally, Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Sanofi has an average rating of "Buy" and an average price target of $62.00.

Sanofi Stock Performance

Shares of SNY stock traded up $1.17 during mid-day trading on Friday, reaching $46.50. 7,259,330 shares of the company's stock traded hands, compared to its average volume of 2,348,687. The firm has a 50 day moving average price of $48.81 and a two-hundred day moving average price of $51.38. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12. The firm has a market capitalization of $114.18 billion, a PE ratio of 11.18, a price-to-earnings-growth ratio of 1.10 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business's revenue was down 7.0% on a year-over-year basis. During the same period last year, the company earned $1.73 EPS. On average, research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.